Depletion of Mitogen-Activated Protein Kinase Using an Antisense Oligodeoxynucleotide Approach Downregulates the Phenylephrine-Induced Hypertrophic Response in Rat Cardiac Myocytes
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
An antisense oligodeoxynucleotide (ODN) approach was used to investigate whether mitogen-activated protein kinase (MAPK) is necessary for the hypertrophic response in cardiac myocytes. A phosphorothioate-protected 17-mer directed against the initiation of translation sites of the p42 and p44 MAPK isoform mRNAs was introduced into cultured cardiac myocytes by liposomal transfection. At an antisense ODN concentration of 0.2 μmol/L, p42 MAPK protein was reduced by 82% (immunoblot) after 48 hours, and p42 and p44 MAPK activities were reduced by 44% and 60%, respectively. The same concentration of anti-MAPK ODN inhibited development of the morphological features of hypertrophy (sarcomerogenesis, increased cell size) in myocytes exposed to phenylephrine. Phenylephrine-induced activation of the atrial natriuretic factor (ANF) promoter (measured by the activity of a transfected ANF promoter/luciferase reporter gene) and induction of ANF mRNA (measured by RNase protection assay) were also attenuated. We conclude that MAPK is important for the development of the hypertrophic phenotype in this model of hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simpson, P., & Savion, S. (1982) · Circulation Research · doi:10.1161/01.res.50.1.101 · Cited by 453
Cited by
Left Ventricular Remodeling After Myocardial Infarction: Pathophysiology and Therapy
Sutton, M. G. S. J., & Sharpe, N. (2000) · Circulation · doi:10.1161/01.cir.101.25.2981 · Cited by 1,824
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
Bueno, O. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.23.6341 · Cited by 774
Cytoplasmic Signaling Pathways That Regulate Cardiac Hypertrophy
Molkentin, J. D., & Dorn II, G. W. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.391 · Cited by 689
Cellular mechanisms of cardiac hypertrophy
Sugden, P. H., & Clerk, A. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050275 · Cited by 404
Self-citationInvolvement of Extracellular Signal-Regulated Kinases 1/2 in Cardiac Hypertrophy and Cell Death
Bueno, O. F., & Molkentin, J. D. (2002) · Circulation Research · doi:10.1161/01.res.0000038488.38975.1a · Cited by 397
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 318
Multiple Signal Transduction Pathways Link Na+/K+-ATPase to Growth-related Genes in Cardiac Myocytes
Kometiani, P., Li, J., Gnudi, L., Kahn, B. B., Askari, A., & Xie, Z. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15249 · Cited by 305
Knowles, J. W., Esposito, G., Mao, L., Hagaman, J. R., Fox, J. E., Smithies, O., Rockman, H. A., & Maeda, N. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11273 · Cited by 302
Woodman, S. E., Park, D. S., Cohen, A. W., Cheung, M. W.-C., Chandra, M., Shirani, J., Tang, B., Jelicks, L. A., Kitsis, R. N., Christ, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205511200 · Cited by 286
The mechanosensitive Piezo1 channel mediates heart mechano-chemo transduction
Jiang, F., Yin, K., Wu, K., Zhang, M., Wang, S., Cheng, H., Zhou, Z., & Xiao, B. (2021) · Nature Communications · doi:10.1038/s41467-021-21178-4 · Cited by 283
Liang, Q., Wiese, R. J., Bueno, O. F., Dai, Y.-S., Markham, B. E., & Molkentin, J. D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7460-7469.2001 · Cited by 271
Purcell, N. H., Wilkins, B. J., York, A., Saba-El-Leil, M. K., Meloche, S., Robbins, J., & Molkentin, J. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610906104 · Cited by 246
Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells
Lin, H.-Y., Davis, F. B., Gordinier, J. K., Martino, L. J., & Davis, P. J. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.276.5.c1014 · Cited by 239
The Molecular Basis for Distinct β-Adrenergic Receptor Subtype Actions in Cardiomyocytes
Steinberg, S. F. (1999) · Circulation Research · doi:10.1161/01.res.85.11.1101 · Cited by 228
Graf, K., Xi, X.-P., Yang, D., Fleck, E., Hsueh, W. A., & Law, R. E. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.334 · Cited by 217
Signaling in Myocardial Hypertrophy: Life After Calcineurin?
Sugden, P. H. (1999) · Circulation Research · doi:10.1161/01.res.84.6.633 · Cited by 197
Self-citationMitogen-activated protein kinases: A new therapeutic target in cardiac pathology
Ravingerová, T., Barančík, M., & Strnisková, M. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1024119224033 · Cited by 175
“in hypertrophic responses was also demonstrated using antisense oligodeoxynucleotide approach, when anti-MAPK oligodeoxynucleotide inhibited the development of morphological features of hypertrophy in cardiomyocytes exposed to phenylephrine [67].”
Metadata
- Authors
- Glennon, P. E., Kaddoura, S., Sale, E. M., Sale, G. J., Fuller, S. J., & Sugden, P. H.
- Venue
- Circulation Research
- Published
- 1996-06
- Volume
- 78
- Issue
- 6
- Pages
- 954-961
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2118634133
- Cited by
- 206
- References
- 1
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.